Practice pathway and effectiveness evaluation of GCP resident pharmacists in the management of dermatological drug clinical trials

WANG Yunlong; ZHOU Limin; ZHANG Hua; LI Quanchao

doi:10.6039/j.issn.1001-0408.2025.20.04

您当前的位置：

首页 >

文章列表页 >

Practice pathway and effectiveness evaluation of GCP resident pharmacists in the management of dermatological drug clinical trials

更新时间：2025-10-25

- Practice pathway and effectiveness evaluation of GCP resident pharmacists in the management of dermatological drug clinical trials
- ZHONGGUO YAOFANG Vol. 36, Issue 20, Pages: 2507-2511(2025)
- 作者机构：
  
  南阳市第一人民医院药学部，河南南阳　473010
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.20.04
  CLC： R95;R969.4
- Received：19 June 2025，
  
  Revised：2025-09-20，
  
  Accepted：23 September 2025，
  
  Published：30 October 2025
- 稿件说明：
移动端阅览
王云龙,周立敏,章华,等.GCP驻科药师在皮肤病专业药物临床试验管理中的实践路径与效果评价 [J].中国药房,2025,36(20):2507-2511.

WANG Yunlong,ZHOU Limin,ZHANG Hua,et al.Practice pathway and effectiveness evaluation of GCP resident pharmacists in the management of dermatological drug clinical trials[J].ZHONGGUO YAOFANG,2025,36(20):2507-2511.
王云龙,周立敏,章华,等.GCP驻科药师在皮肤病专业药物临床试验管理中的实践路径与效果评价 [J].中国药房,2025,36(20):2507-2511. DOI： 10.6039/j.issn.1001-0408.2025.20.04.

WANG Yunlong,ZHOU Limin,ZHANG Hua,et al.Practice pathway and effectiveness evaluation of GCP resident pharmacists in the management of dermatological drug clinical trials[J].ZHONGGUO YAOFANG,2025,36(20):2507-2511. DOI： 10.6039/j.issn.1001-0408.2025.20.04.

摘要

目的

探索药物临床试验机构办公室驻科药师（下称“GCP驻科药师”）在皮肤病专业药物临床试验管理中的实践路径并评价其效果。

方法

对我院GCP驻科药师参与皮肤病专业药物临床试验的实践路径进行介绍；回顾性分析2021－2024年我院皮肤病专业药物临床试验相关数据，对比皮肤病专业药物临床试验项目与其他专业项目的效率指标和质量指标。

结果

我院GCP驻科药师全程参与皮肤病专业药物临床试验的流程建设和优化，建立该专业药物临床试验专属质控体系，并优化该专业药物临床试验受试者入组加速策略。GCP驻科药师工作开展后，2021－2023年我院皮肤病专业药物临床试验项目数的复合年均增长率为69.56%。效率指标方面，皮肤病专业药物临床试验项目的立项等待时间为（12.31±4.99）d，显著短于其他专业项目的（19.68±6.09）d（

＜0.05）。质量指标方面，皮肤病专业药物临床试验项目入组率为75.71%（50.00%，114.48%），显著高于其他专业项目的51.00%（25.00%，174.17%）（

＜0.05）；首次质控问题条目数[（8.31±3.25）条vs. （11.68±4.49）条

]

、方案偏离次数[5.5（2.0，11.0）次vs. 11.0（5.5，17.5）次

]

均显著少于其他专业项目（

＜0.05）。

结论

GCP驻科药师显著提升了皮肤病专业药物临床试验的整体效能，对确保药物临床试验可靠、真实，保障受试者权益、安全具有重要作用。

Abstract

OBJECTIVE

To explore the practice pathway and evaluate the effectiveness of the resident pharmacists stationed in the Drug Clinical Trial Institution Office （hereinafter referred to as the “GCP resident pharmacist”） in the management of dermatological drug clinical trials.

METHODS

The practical approach of GCP resident pharmacists participating in dermatological drug clinical trials at our hospital was introduced. A retrospective analysis was conducted on the data of dermatological drug clinical trials from 2021 to 2024， comparing efficiency and quality indicators between dermatological clinical trials and those of other specialties.

RESULTS

With the involvement of our hospital’s GCP resident pharmacists throughout

the process for dermatology drug clinical trials was constructed and optimized， a dedicated quality control system was established， and the acceleration strategy for subject enrollment was optimized. The number of dermatological drug clinical trials at our hospital showed a compound annual growth rate of 69.56% from 2021 to 2023. In terms of efficiency indicators， the approval waiting time for dermatological drug clinical trials was （12.31±4.99） days， which was significantly shorter than that of other specialties [（19.68±6.09） days，

＜0.05

]

. Regarding quality indicators， the enrollment rate for dermatological drug clinical trials was 75.71%（50.00%，114.48%）， which was significantly higher than that of other specialties [51.00%（25.00%，174.17%），

＜0.05

]

. The numbers of first quality control issues [（8.31±3.25）items vs. （11.68±4.49）items

]

and protocol deviations [5.5（2.0，11.0）times vs. 11.0（5.5，17.5）times

]

were significantly lower than those of other specialties （

＜0.05）.

CONCLUSIONS

GCP resident pharmacists significantly enhance the overall efficiency of dermatological drug clinical trials， playing a crucial role in ensuring the reliability and authenticity of drug clinical trials， as well as safeguarding the rights and safety of trial subjects.

关键词

Keywords

references

国家药监局，国家卫生健康委 . 国家药监局国家卫生健康委关于发布药物临床试验机构管理规定的公告 [EB/OL ] .（ 2019-11-29 ）[ 2025-06-16 ] . https：//www.gov.cn/gongbao/content/2020/content_5496785.htm https://www.gov.cn/gongbao/content/2020/content_5496785.htm .

石真玉，霍乐淳，周姚，等 . 中国新备案药物临床试验机构及其临床试验开展情况分析 [J ] . 中国食品药品监管， 2023 （ 3 ）： 50 - 57 ， 142 - 143 .

国家药监局，国家卫生健康委 . 国家药监局国家卫生健康委关于发布药物临床试验质量管理规范的公告 [EB/OL ] .（ 2020-04-23 ）[ 2025-06-16 ] . https：//www.gov.cn/gongbao/content/2020/content_5525106.htm https://www.gov.cn/gongbao/content/2020/content_5525106.htm .

周城，赵琰，蔡林，等 . 中国皮肤科新药研发10年回顾 [J ] . 中国新药杂志， 2023 ， 32 （ 19 ）： 1905 - 1908 .

翟云，徐鹏遥，钱思源，等 . 中国皮肤科药物创新研发及审评审批进展 [J ] . 中国新药杂志， 2023 ， 32 （ 19 ）： 1909 - 1914 .

王海坤，王婕，吴娜，等 . JAK抑制剂治疗白癜风的研究进展 [J ] . 中国药房， 2020 ， 31 （ 16 ）： 2043 - 2048 .

孙闻续，游欣月，江弦，等 . 驻科药师制度下主动式出院带药医嘱审核和用药教育服务模式研究 [J ] . 中国药房， 2025 ， 36 （ 10 ）： 1243 - 1247 .

国家卫生健康委医学伦理专家委员会办公室，中国医院协会 . 关于公布《涉及人的临床研究伦理审查委员会建设指南（2020版）》的通知 [EB/OL ] .（ 2020-10-26 ）[ 2025-06-16 ] . https：//www.cha.org.cn/site/content/9a09eb3ab4a-7153b7beeec07be5e0b3f.html https://www.cha.org.cn/site/content/9a09eb3ab4a-7153b7beeec07be5e0b3f.html .

邱博，杜润璇，杨浩天，等 . 基于风险的药物临床试验方案偏离管理模式探讨 [J ] . 中南药学， 2023 ， 21 （ 9 ）： 2524 - 2528 .

谭琴，邱攀博，李高扬，等 . 药物临床试验机构质量管理现状调查分析 [J ] . 医药导报， 2023 ， 42 （ 12 ）： 1884 - 1889 .

黄樱硕，汪颖，张健雄，等 . 北京某医院示范性研究型病房“共享综合服务”医疗实践 [J ] . 中国医院， 2021 ， 25 （ 11 ）： 55 - 57 .

彭思意，陈勇，魏涛，等 . 以护士为主导的抗肿瘤药物Ⅰ期临床试验全程化管理模式的建立与实施 [J ] . 全科护理， 2023 ， 21 （ 9 ）： 1237 - 1241 .

郑航，徐宏琳，汤安邦，等 . 我国CRA/CRC执业现状与态度比较研究 [J ] . 中国处方药， 2021 ， 19 （ 5 ）： 33 - 37 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on HPLC fingerprint and quantitative analysis of multi-components by single-marker content determination method for Shechuan naolitong granules

Evaluation of the quality of Alpinia katsumadai from different habitats based on HPLC fingerprint and determination of active ingredient content

Comparison of HPLC fingerprint and contents of four nucleoside components before and after processing of Succus bambusae pinella preparata

Extraction， isolation， identification and content determination of four chemical components in Yao medicine Ventilago leiocarpa

Study on quality control method of the roots and rhizoma of Toricellia angulata

Related Author

ZHANG Xiaoyan

DING Kairu

ZHANG Hong

ZHI Wenbing

JIANG Shengnan

XU Zongren

CUI Ni

WEI Xiangfeng

Related Institution

Xi’an TCM Preparation Engineering Technology Research Center

Medicine Preparation Center， Xi’an TCM Hospital of Encephalopathy

College of Life Science， Northwest University

Institute of Chinese Materia Medica， Shaanxi Academy of Traditional Chinese Medicine （Shaanxi Hospital of TCM）

The First Clinical Medical College， Nanjing University of Chinese Medicine

⁰